Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 42

Results For "EY"

3109 News Found

Arvinas and Pfizer presents phase 1b data from the TACTIVE-U sub-study of Vepdegestrant in combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium
Diagnostic Center | December 11, 2024

Arvinas and Pfizer presents phase 1b data from the TACTIVE-U sub-study of Vepdegestrant in combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium

Vepdegestrant in combination with abemaciclib demonstrated encouraging clinical activity (clinical benefit rate


Suven to acquire 56% stake in ADC specialist NJ Bio for US$64.4 million
News | December 09, 2024

Suven to acquire 56% stake in ADC specialist NJ Bio for US$64.4 million

This acquisition positions Suven as a key player in one of the fastest growing segments of the Pharma CDMO landscape


AbbVie announces emotional impact report on mental health of underrepresented CLL cancer patients
News | December 09, 2024

AbbVie announces emotional impact report on mental health of underrepresented CLL cancer patients

CLL is one of the most common leukemias among adults affecting more than 200,000 people in the US


Supriya Lifescience expands global footprint with Esketamine Hydrochloride approval
News | December 09, 2024

Supriya Lifescience expands global footprint with Esketamine Hydrochloride approval

Esketamine hydrochloride is a vital drug to be used for treating mental illness and is likely to significantly impact the LATAM market


Briefs: Venus Remedies and GPT Healthcare
News | December 07, 2024

Briefs: Venus Remedies and GPT Healthcare

Venus Remedies secures marketing authorization in Philippines


NTC presents positive results from Phase II Mirakle study evaluating an innovative drug for bacterial conjunctivitis
News | December 07, 2024

NTC presents positive results from Phase II Mirakle study evaluating an innovative drug for bacterial conjunctivitis

Despite NTC014, due to its simplified therapeutic regimen, has been administered at a lower posology than the antibiotic comparator


Alembic Pharmaceuticals gets USFDA tentative approval for OTC
Drug Approval | December 05, 2024

Alembic Pharmaceuticals gets USFDA tentative approval for OTC

Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC) is used to temporarily relieve itchy eyes due to pollen, ragweed, grass, animal hair and dander


Granules India update on USFDA inspection at Gagillapur facility
News | December 05, 2024

Granules India update on USFDA inspection at Gagillapur facility

Granules has undertaken a proactive, voluntary and comprehensive remediation plan to address the six form 483 observations raised by the USFDA